ReviewJournal of clinical medicine2025
Redefining Aortic Valve Replacement: The Transition from Open Surgery to Transcatheter Innovation.
Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evolution of Aortic Valve Replacement Across Two Eras: Institutional Changes in Transcatheter and Surgical Practice and Outcomes.Medical sciences (Basel, Switzerland) · 2026Article
- Transcatheter Aortic Valve Replacement Within a Structured Secondary Prevention Framework in Cardiovascular Disease.Cureus · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aortic valve replacement (AVR) has evolved dramatically, transitioning from open surgery to minimally invasive and transcatheter approaches. This review examines the historical and technological advancements in AVR, focusing on the evolution of mechanical and bioprosthetic valves, valve-sparing techniques, and the Ross procedure. Mechanical valves offer superior durability but require lifelong anticoagulation, while bioprosthetic valves avoid this need at the expense of long-term durability. Transcatheter aortic valve replacement (TAVR), originally reserved for high-risk patients, is now used across all risk profiles due to growing evidence of safety and efficacy from major trials like PARTNER and Core Valve. Despite its benefits, TAVR presents some challenges, including paravalvular leak, pacemaker implantation, and uncertain long-term durability, especially in younger patients. Valve-in-valve techniques, novel valve designs, and anti-calcification treatments offer promising solutions. Looking forward, the integration of artificial intelligence and personalized procedural planning will play a key role in optimizing outcomes. As AVR technology advances, careful patient selection and a multidisciplinary approach remain essential to guiding individualized treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.